Companies › Tianjin ConjuStar Biologics
2 active drug programs in 3 registered trials: 2 Phase 1, 1 Phase 2; Oncology; next expected readout Mar 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| SC-101 anti-NECTIN4 antibody-drug conjugate | NECTIN4 | Phase 2 | TNBC - Triple-Negative Breast Cancer; Advanced Solid Tumor | Mar 2027 |
| SC-102 EphA2-targeting peptide conjugate with tubulin inhibitor | EPHA2 | Phase 1 | Advanced Solid Cancers | Jun 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06220838 | SC-101 | Phase 1 | Advanced Solid Tumor | Oncology | Mar 2027 |
| NCT06710158 | SC-102 | Phase 1 | Advanced Solid Cancers | Oncology | Jun 2027 |
| NCT07080619 | SC-101 | Phase 2 | TNBC - Triple-Negative Breast Cancer | Oncology | Jul 2027 |
BicycleTx Mabwell (Shanghai) Bioscience Aktis Oncology Regeneron Pharmaceuticals Innate Pharma Astellas Samsung Bioepis Beijing Biotech Akeso Context Therapeutics
Innate Pharma BicycleTx Zhejiang Hisun Pharmaceutical Acrivon Therapeutics Stemline Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.